Form 4: Intra-Cellular Therapies President Sells Shares Under 10b5-1 Plan

Intra-Cellular Therapies' President, Michael Halstead, executed multiple sales of company stock under a pre-arranged 10b5-1 trading plan.

Summary

• Michael Halstead, President of Intra-Cellular Therapies, Inc., sold a total of 31,403 shares of common stock on November 12th and 13th, 2024.
• These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 13, 2024.
• The sales occurred in multiple transactions at varying prices, with weighted average prices reported for each day.
• On November 12th, 2024, 22,869 shares were acquired through option exercise at $23.94 per share and then 22,869 shares were sold in multiple transactions at weighted average prices of $88.72, $89.63 and $90.89.
• On November 13th, 2024, 18,714 shares were acquired through option exercise at $36.89 per share and then 18,714 shares were sold in multiple transactions at weighted average prices of $88.17 and $88.92.
• The reporting person also acquired 22,869 and 18,714 shares through the exercise of stock options on November 12th and 13th respectively.
• The stock options were exercised at prices of $23.94 and $36.89 respectively.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing stock sales by an executive under a pre-arranged plan. It doesn't indicate any positive or negative sentiment, it is a neutral event.

Risks

• Executive stock sales can sometimes be perceived negatively by the market, potentially impacting investor sentiment.

Industry Context

This is a routine filing related to executive stock transactions and is common in the pharmaceutical industry where stock options are a significant part of compensation.

Comparison to Industry Standards

• Executive stock sales under 10b5-1 plans are a common practice across publicly traded companies, including those in the pharmaceutical sector.
• Companies like Eli Lilly, Pfizer, and AbbVie also have executives who utilize similar trading plans to manage their stock holdings.
• The reported prices are within the typical range for stock sales by executives in the pharmaceutical industry.

Stakeholder Impact

• The stock sales may have a minor impact on the stock price, but the pre-arranged nature of the sales should mitigate any significant negative reaction from shareholders.

Key Dates

Keywords

Intra-Cellular Therapies, Michael Halstead, stock sale, Form 4, Rule 10b5-1, insider trading, stock options, executive compensation